In this video from The Motley Fool's "Ask a Fool" series, Fool health-care analyst Max Macaluso takes a question from a Fool reader, who asks, "What is your Foolish opinion of Horizon Pharma ?" This commercial-stage biotech company has seen its shares blow through the roof over the past year, up a staggering 475% over the past 12 months. What has driven this white-hot run, and is there still time for investors to get in? Max breaks the company's success down to three key factors that investors need to be aware of, and isolates one major risk shareholders could face from here.
What's the best way for investors to play the biotech game?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Ask a Fool: What Is Your Foolish Opinion of Horizon Pharma? originally appeared on Fool.com.Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.